Palisade Bio Statistics

Total Valuation

Palisade Bio has a market cap or net worth of $3.24 million. The enterprise value is -$3.93 million.

Market Cap	3.24M
Enterprise Value	-3.93M

Important Dates

The last earnings date was Monday, May 12, 2025, after market close.

Earnings Date	May 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Palisade Bio has 4.40 million shares outstanding. The number of shares has increased by 320.63% in one year.

Current Share Class	4.40M
Shares Outstanding	4.40M
Shares Change (YoY)	+320.63%
Shares Change (QoQ)	+121.91%
Owned by Insiders (%)	0.50%
Owned by Institutions (%)	2.79%
Float	3.90M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.61
P/TBV Ratio	0.61
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.84, with a Debt / Equity ratio of 0.01.

Current Ratio	2.84
Quick Ratio	2.60
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,124.67

Financial Efficiency

Return on equity (ROE) is -170.72% and return on invested capital (ROIC) is -107.89%.

Return on Equity (ROE)	-170.72%
Return on Assets (ROA)	-80.94%
Return on Invested Capital (ROIC)	-107.89%
Return on Capital Employed (ROCE)	-249.33%
Revenue Per Employee	n/a
Profits Per Employee	-$1.64M
Employee Count	8
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -88.41% in the last 52 weeks. The beta is 1.33, so Palisade Bio's price volatility has been higher than the market average.

Beta (5Y)	1.33
52-Week Price Change	-88.41%
50-Day Moving Average	0.75
200-Day Moving Average	2.07
Relative Strength Index (RSI)	49.37
Average Volume (20 Days)	396,799

Short Selling Information

The latest short interest is 40,926, so 0.93% of the outstanding shares have been sold short.

Short Interest	40,926
Short Previous Month	53,241
Short % of Shares Out	0.93%
Short % of Float	1.05%
Short Ratio (days to cover)	0.88

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-13.50M
Pretax Income	-13.50M
Net Income	-13.14M
EBITDA	-13.49M
EBIT	-13.50M
Earnings Per Share (EPS)	-$5.43

Full Income Statement

Balance Sheet

The company has $7.23 million in cash and $58,000 in debt, giving a net cash position of $7.17 million or $1.63 per share.

Cash & Cash Equivalents	7.23M
Total Debt	58,000
Net Cash	7.17M
Net Cash Per Share	$1.63
Equity (Book Value)	5.33M
Book Value Per Share	1.21
Working Capital	5.11M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-11.35M
Capital Expenditures	n/a
Free Cash Flow	-11.35M
FCF Per Share	-$2.58

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Palisade Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-320.63%
Shareholder Yield	-320.63%
Earnings Yield	-405.60%
FCF Yield	-350.20%

Analyst Forecast

The average price target for Palisade Bio is $12.00, which is 1,528.44% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$12.00
Price Target Difference	1,528.44%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-35.22%

Stock Forecasts

Stock Splits

The last stock split was on April 8, 2024. It was a reverse split with a ratio of 0.0666667:1.

Last Split Date	Apr 8, 2024
Split Type	Reverse
Split Ratio	0.0666667:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1